Drug Discovery in the 21st Century
|
Monday June 11, 2012
*Some titles are tentative. Speakers and titles are subject to change
|
|
Session
|
Topic
|
Speaker
|
Company
|
Time
|
| SESSION I - New and Emerging Targets in Oncology |
|
Discovery and SAR exploration of a novel series of potent and selective mTOR kinase inhibitors |
Deborah Mortensen
|
Celgene
|
|
| |
Discovery of Orally Bioavailable, Small-Molecule Inhibitors of Anaplastic Lymphoma Kinase (ALK)
|
Greg Ott
|
Cephalon
|
|
|
Progress in targeted covalent inhibitors in oncology
|
TBD
|
Avila
|
|
|
Antibody Drug Conjugates: A new Horizon for Cancer Treatment
|
Chakrapani Subramanyam
|
Pfizer
|
|
| SESSION II - Probes in the Public Sector |
| |
Chemical Probes for Epigenetics
|
Dafydd Owen
|
Pfizer |
|
|
Drug Discovery at the Lieber Institute for Brain Development, a blend of academic and pharma
|
Jim Barrow
|
Johns Hopkins School of Medicine |
|
| SESSION III - CNS - Emerging Targets |
| |
Discovery of Dual Orexin Receptor Antagonists MK-4305 and MK-6096 for the Treatment of Insomnia
|
Chris Cox |
Merck |
|
| KEYNOTE |
Frontiers in Molecular Medicine: Development of Proof-of-Concept Chemical Probes Targeting Cysteine Proteases, Monocarboxylate Transporter-1 (Mct-1), Liver Receptor Homolog-1 (LRH-1) and the Cell Cycle Checkpoint Regulator Wee-1 |
William Roush |
Scripps Florida |
|
|
